Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells

European Journal of Pharmacology

Volumn 462, Issue 1-3, 2003, Pages 15-23

  Bruemmer, Dennis ^a,b   Yin, Fen ^a   Liu, Joey ^a   Kiyono, Tohru ^c   Fleck, Eckart ^b   Van Herle, Andre ^a   Graf, Kristof ^b   Law, Ronald E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

E2F; HMG CoA reductase; Minichromosome maintenance protein; Smooth muscle cell; Vascular

Indexed keywords

ATORVASTATIN; ISOPRENOID; LUCIFERASE; MESSENGER RNA; MEVALONIC ACID; MINICHROMOSOME MAINTENANCE PROTEIN;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPLICATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC TRANSFECTION; HUMAN; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RAT; TRANSCRIPTION INITIATION; VASCULAR SMOOTH MUSCLE;

EID: 0037458589     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01317-7     Document Type: Article

References (48)

1. Agah R., Kirshenbaum L.A., Abdellatif M., Truong L.D., Chakraborty S., Michael L.H., Schneider M.D. Adenoviral delivery of E2F-1 directs cell cycle reentry and p53-independent apoptosis in postmitotic adult myocardium in vivo. J. Clin. Invest. 100:1997;2722-2728.
2. Aparicio O.M., Stout A.M., Bell S.P. Differential assembly of Cdc45p and DNA polymerases at early and late origins of DNA replication. Proc. Natl. Acad. Sci. U. S. A. 96:1999;9130-9135.
3. Bell S.P., Stillman B. ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex. Nature. 357:1992;128-134.
4. Blow J.J., Laskey R.A. A role for the nuclear envelope in controlling DNA replication within the cell cycle. Nature. 332:1988;546-548.
5. Borner M.M., Myers C.E., Sartor O., Sei Y., Toko T., Trepel J.B., Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res. 55:1995;2122-2128.
6. Braun-Dullaeus R.C., Mann M.J., Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 98:1998;82-89.
7. Casey P.J. Protein lipidation in cell signalling. Science. 268:1995;221-225.
8. Coleman T.R., Carpenter P.B., Dunphy W.G. The Xenopus Cdc6 protein is essential for the initiation of a single, round of DNA replication in cell-free extracts. Cell. 87:1996;53-63.
9. Connell-Crowley L., Harper J.W., Goodrich D.W. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Cell. Biol. 8:1997;287-301.
10. Danesh F.R., Sadeghi M.M., Amro N., Philips C., Zeng L., Lin S., Sahai A., Kanwar Y.S. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 99:2002;8301-8305.
11. Diffley J.F., Cocker J.H., Dowell S.J., Rowley A. Two steps in the assembly of complexes at yeast replication origins in vivo. Cell. 78:1994;303-316.
12. Dyson N. The regulation of E2F by pRb-family proteins. Genes Dev. 12:1998;2245-2262.
13. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
14. Hengst L., Reed S.I. Translational control of p27Kip1 accumulation during the cell cycle. Science. 271:1996;1861-1864.
15. Indolfi C., Cioppa A., Stabile E., Di Lorenzo E., Esposito G., Pisani A., Leccia A., Cavuto L., Stingone A.M., Chieffo A., Capozzolo C., Chiariello M. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J. Am. Coll. Cardiol. 35:2000;214-221.
16. Jakobisiak M., Bruno S., Skierski J.S., Darynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc. Natl. Acad. Sci. U. S. A. 88:1991;3628-3632.
17. Jiang W., McDonald D., Hope T.J., Hunter T. Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication. EMBO J. 18:1999;5703-5713.
18. Kearsey S.E., Labib K. MCM proteins: evolution, properties, and role in DNA replication. Biochim. Biophys. Acta. 1398:1998;113-136.
19. Knudson E.S., Wang J.J. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. 271:1996;8313-8320.
20. Kubota Y., Mimura S., Nishimoto S., Takisawa H., Nojima H. Identification of the yeast MCM3-related protein as a component of Xenopus DNA replication licensing factor. Cell. 81:1995;601-609.
21. Labib K., Tercero J.A., Diffley J.F. Uninterrupted MCM2-7 function required for DNA replication fork progression. Science. 288:2000;1643-1647.
22. kip1. J. Biol. Chem. 274:1999;21926-21931.
23. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
24. Mimura S., Takisawa H. Xenopus Cdc45-dependent loading of DNA polymerase onto chromatin under the control of S-phase Cdk. EMBO J. 17:1998;5699-5707.
25. Ohtani K., Iwanaga R., Nakamura M., Ikeda M., Yabuta N., Tsuruga H., Nojima H. Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F. Oncogene. 18:1999;2299-2309.
26. Olson M.F., Ashworth A., Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 269:1995;1270-1272.
27. Packard C.J. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
28. Park C., Lee I., Kang W.K. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis. 22:2001;1727-1731.
29. Raiteri M., Arnaboldi L., McGeady P., Gelb M.H., Verri D., Talgiabue C., Quarato P., Ferraboschi P., Santaniello E., Paoletti R., Fumagalli R., Corsini A. Pharmacological control of the mevalonate pathway. Effect of arterial smooth muscle cell proliferation. J. Pharmacol. Exp. Ther. 281:1997;1144-1153.
30. Ross R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 57:1995;791-804.
31. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M.O., Wun C.C., Davis B.R., Braunwald E. Cholesterol and recurrent event trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
32. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
33. Seasholtz T.M., Zhang T., Morissette M.R., Howes A.L., Yang A.H., Brown J.H. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ. Res. 89:2001;488-495.
34. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., McKillop J.H., Packard C.W. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1995;1301-1307.
35. Sindermann J.R., Fan L., Weigel K.A., Troyer D., Müller J.G., Schmidt A., March K.L., Breithardt G. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis. 150:2000;331-341.
36. Soma M.R., Donetti E., Parolino C., Mazzini G., Ferrari C., Fumagalli R., Paoletti R. HMG-CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler. Thromb. 13:1993;571-578.
37. Stillman B. Cell cycle control of DNA replication. Science. 274:1996;1659-1664.
38. Suzuki S., Adachi A., Hiraiwa A., Ohashi M., Ishibashi M., Kiyono T. Cloning and characterization of human MCM7 promoter. Gene. 216:1998;85-91.
39. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21:2001;1712-1719.
40. Takisawa H., Mimura S., Kubota Y. Curr. Opin. Cell Biol. 12:2000;690-696.
41. Tye B.K. MCM proteins in DNA replication. Annu. Rev. Biochem. 68:1999;649-686.
42. Walter J., Newport J. Initiation of eukaryotic DNA replication: origin unwinding and sequential chromatin association of Cdc45, RPA, and DNA polymerase alpha. Mol. Cell. 5:2000;617-627.
43. Weiss R.H., Ramirez A., Joo A. Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signalling proteins p27Kip1 and PI3 kinase. J. Am. Soc. Nephrol. 10:1999;1880-1890.
44. Weinberg R.A. E2F and cell proliferation: a world turned upside down. Cell. 85:1996;457-459.
45. Welsh C.F., Roovers K., Villanueva J., Liu Y., Schwartz M.A., Assoian R.K. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat. Cell Biol. 3:2001;950-957.
46. Yang Z., Kozai T., van de Loo B., Viswambharan H., Lachat M., Turina M.I., Malinski T., Lüscher T.F. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J. Am. Coll. Cardiol. 36:2000;1691-1697.
47. You Z., Komamra Y., Ishimi Y. Biochemical analysis of the intrinsic Mcm4-Mcm6-Mcm7 DNA helicase activity. Mol. Cell. Biol. 19:1999;8003-8015.
48. Zou L., Stillman B. Formation of preinitiation complex by S-phase cyclin CDK-dependent loading of Cdc45p onto chromatin. Science. 280:1998;593-596.